DOACs: 60 Second Insights
Published: 18 June 2018
-
Views:
669
-
Likes:
7
-
Views:
669
-
Likes:
7
-
Up Next -
38sPart 1 | Session 10 Is RCT or real-world data more important to you? - Christopher Cannon
-
1m 3sPart 1 | Session 11 Is RCT or real-world data more important to you? - Moussa Mansour
-
50sPart 1 | Session 1 What are the challeges of DOACs and are alternatives needed? Christopher P Cannon
-
46sPart 1 | Session 2 What factors influence your choice of DOAC? Christopher P Cannon
-
46sPart 1 | Session 3 Do you have a DOAC you prescribe more frequently? Christopher P Cannon
-
46sPart 1 | Session 4 What are the most important anticoagulation clinical trials? Christopher P Cannon
-
45sPart 1 | Session 5 Do you have a DOAC of choice? Moussa Mansour
-
41sPart 1 | Session 6 How important are reversal agents? - Christoper Cannon Christopher P Cannon
-
42sPart 1 | Session 7 How important are reversal agents? - Moussa Mansour Moussa Mansour
-
36sPart 1 | Session 8 Are you once-daily or twice-daily? - Christopher Cannon Christopher P Cannon
Overview
Christopher Cannon and Moussa Mansour share their thoughts on DOACs in a series of 60-second interviews
More from this programme
Part 1
DOACs
Faculty Biographies
Moussa Mansour
Associate Professor of Medicine
Dr Moussa Mansour is the Director of the Cardiac Electrophysiology Laboratory and Director of the Atrial Fibrillation Program at Massachusetts General Hospital. Dr Mansour has published extensively in the field of cardiac arrhythmia, specifically the area of atrial fibrillation. He is involved in cutting edge research and currently participating in the development of new catheters for the treatment of atrial fibrillation.